56290-94-9
56290-94-9 structure
- Name: 5-[2-[[3-(1,3-benzodioxol-5-yl)-1-methylpropyl]amino]-1-hydroxyethyl]salicylamide
- Chemical Name: 5-[2-[4-(1,3-benzodioxol-5-yl)butan-2-ylamino]-1-hydroxyethyl]-2-hydroxybenzamide
- CAS Number: 56290-94-9
- Molecular Formula: C20H24N2O5
- Molecular Weight: 372.41500
- Catalog: Signaling Pathways GPCR/G Protein Adrenergic Receptor
- Create Date: 2018-09-16 17:49:27
- Modify Date: 2024-01-11 14:34:07
-
Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist, blocks α- and β-adrenergic receptors. Medroxalol shows antihypertensive and vasodilating effects[1].
| Name | 5-[2-[4-(1,3-benzodioxol-5-yl)butan-2-ylamino]-1-hydroxyethyl]-2-hydroxybenzamide |
|---|---|
| Synonyms |
RMI 81,968
MEDROXALOL EINECS 260-099-3 Medroxalolum |
| Description | Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist, blocks α- and β-adrenergic receptors. Medroxalol shows antihypertensive and vasodilating effects[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Medroxalol (0.1-10 μM; 20 min) shows α- and β-adrenergic receptor antagonism in isolated rabbit aortic strip[1]. Cell Viability Assay[1] Cell Line: Isolated rabbit aortic strip Concentration: 0.1-10 μM Incubation Time: 20 min Result: Showed pA2 values of 6.09 and 7.73 for α-adrenergic receptors and β-adrenergic receptors, respevtively. |
| In Vivo | Medroxalol (oral gavage; 12.5-50 mg/kg; once daily; 12 d) treatment shows antihypertensive activity in spontaneously hypertensive rats[1]. Animal Model: Male spontaneously hypertensive rats (SHR)[1] Dosage: 12.5, 25, or 50 mg/kg Administration: Oral gavage; 12.5, 25, or 50 mg/kg; once daily; 12 days Result: Produced a dose-related fall in blood pressure. |
| Density | 1.307g/cm3 |
|---|---|
| Boiling Point | 604.1ºC at 760 mmHg |
| Molecular Formula | C20H24N2O5 |
| Molecular Weight | 372.41500 |
| Flash Point | 319.1ºC |
| Exact Mass | 372.16900 |
| PSA | 114.04000 |
| LogP | 2.95530 |
| Index of Refraction | 1.626 |
|
~84%
56290-94-9 |
| Literature: Grisar; Claxton; Bare; Dage; Cheng; Woodward Journal of Medicinal Chemistry, 1981 , vol. 24, # 3 p. 327 - 336 |
| Precursor 1 | |
|---|---|
| DownStream 0 | |